Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary endpoint of a statistically significant increase in salivary flow production compared to placebo at all three doses: 10 mg, 15 mg, and 20 mg. These doses were safe and well tolerated with few reports of excessive sweating and gastrointestinal complaints.

"The preliminary data look very impressive and offer new hope to patients with Sjogren's syndrome," said principal investigator Frederick B. Vivino, M.D., Chief, Division of Rheumatology, Penn Presbyterian Medical Center, Clinical Associate Professor of Medicine, University of Pennsylvania School of Medicine and Director of the Penn Sjogren's Syndrome Center. "NGX267 appears to be efficacious, safe and well tolerated in short term use. The results of this recently completed clinical trial undoubtedly justify the design and execution of longer placebo-controlled trials in a larger group of Sjogren's syndrome patients. This will help us better elucidate the full benefit of this novel treatment."

"The findings from this study are very promising given the demonstrated efficacy and low incidence of adverse events for the three doses of NGX267," said Ev Graham, Chief Executive Officer of TorreyPines. "Moving forward, we now have data that suggests this well-tolerated product candidate could be effective in treating dry mouth associated with Sjogren's syndrome, and possibly other conditions in which a reduction in salivary flow has been observed such as the effects of head and neck radiation, diabetes and aging. According to our preliminary market research, there is a significant need f
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... OAKS, Calif. , May 16, 2013  Amgen (NASDAQ: ... Life Sciences Conference on Tuesday, May 21, 2013, at the ... City , beginning at 10:00 a.m. Eastern Daylight Time. ... vice president of Research and Development at Amgen, will present ... accessed from the Events Calendar on Amgen,s website, www.amgen.com ...
(Date:5/16/2013)... , May 16, 2013 ... in the U.S. to access the widely-used OrthoView digital ... PC and Internet connection to get started. ... software for over 10 years, is dedicated to enabling ... with digital x-ray images, when printed film is unavailable. ...
(Date:5/16/2013)... , May 16, 2013 Developers of a pill ... reminders have emerged as grand prize winners in the ... funded by Boehringer Ingelheim and organized by HITLAB . ... , John Langhauser and ... the United States will receive $50,000 ...
Breaking Medicine Technology:OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5
... Johnson & Johnson Pharmaceutical,Research & Development, L.L.C. ... showed that investigational antibiotic ceftobiprole was found to,clinically ... -- including,some infections that were caused by methicillin-resistant ... the 45th annual meeting of the Infectious,Disease Society ...
... 3 clinical development program will examine HZT-501 as ... NSAID for mild to moderate pain -, ... Inc., a,privately held biopharmaceutical company, today announced that ... (protocol HZ-CA-304) of its lead,product candidate HZT-501, an ...
Cached Medicine Technology:New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 2New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 3New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 4Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 2Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 3
(Date:5/19/2013)... May 19, 2013 According to ... Analysis and Forecast (2013 – 2018): By Applications ... Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) ... image sensor market was $8.00 billion in 2012 ... 2018, at an estimated CAGR of 3.84% from ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... note that a Case Management Conference was recently convened ... in a federal multidistrict litigation now underway in U.S. ... Minutes posted on the Court’s website on May 14th, ... motions. It was also reported during the Conference ...
(Date:5/19/2013)... Vegas Hotel Escapes, the premier Las ... launch it's all new vacation packages for the upcoming ... Consumers traveling to Las Vegas will be pleased to ... website. Travelers will be pleased to know that VegasHotelEscapes.com ... Vegas Hotel Escapes specializes in helping consumers Las ...
(Date:5/19/2013)... Beginning Wednesday, May 29 and running through Wednesday, August ... “Hot Dog Wednesdays" and Ice Cold Slushies at donor centers ... and all the fixin's to donors on Wednesdays. RRVBC ... “Donors are our lifeline. The summer months are an especially ... This is a small way for us to thank ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... Live Event ... Optimize Available Resources , ... VA (PRWEB) May 11, 2010 -- Harmony Information Systems Inc ., the leader in ... Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management ,” scheduled for Wednesday, May ...
... ... an Interpretive Dance Video. , ... Seattle, WA (PRWEB) May 11, 2010 -- Onlineshoes.com is proud to announce ... campaign featuring an interpretive dance video. , , ,Pronounced “cushy”, Cushe is a ...
... ... been recognized as a silver SugarCRM implementation partner providing best-practice implementation services ... the last two years as a leading player in producing advanced sales and marketing ... ...
... Melanoma and ... is linked to cancer risk. Practical and clinical information about skin health, melanoma and skin ... , ... -- With skin cancer on the rise for Americans under 30 and indoor tanning contributing ...
... ... million in a medical malpractice case against an obstetrician who delayed a C-section while the baby ... Division, Essex County, Docket No.: ESX-L-1906-08. , ... (PRWEB) May 11, 2010 -- On April 29, 2010 an Essex County, New Jersey jury ...
... ... noise , ... 11, 2010 -- Noisy construction by the MTA is keeping some residents in Brooklyn up ... have had no effect. Construction accident attorneys in New York are familiar with the ...
Cached Medicine News:Health News:Harmony Information Systems to Host Free Webcast: Learn How Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management 2Health News:Harmony Information Systems to Host Free Webcast: Learn How Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management 3Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 3Health News:ApexTwo and SugarCRM Announce New Implementation Partnership 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 3Health News:$18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section 2Health News:New York Construction Accident Attorney, David Perecman, Supports MTA Night Work 2
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... Burgdorferi Antibody Detection Assay is a single ... presumptive (first step) detection of IgG and ... serum or whole blood. Rapid turnaround time, ... the Wampole PreVue B. burgdorferi antibody detection ...
Medicine Products: